# Ossianix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ossianix

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.ossianix.com
- Latest round: Seed (May 23, 2013)
- Investors on record: 1

## About

Ossianix, Inc. focuses on innovative therapeutic solutions through the targeted delivery of biologics, utilizing proprietary technology to overcome the challenges of the blood-brain barrier for neurological treatments.Founded in 2011 and headquartered in Philadelphia, US, Ossianix, Inc. specializes in drug delivery systems, specifically targeting the central nervous system. The company was co-founded by Frank Walsh and Lynn Rutkowski. Since its inception, Ossianix has completed 3 deals, with its most recent deal occurring on October 24, 2014.Ossianix specializes in the development of a unique therapeutic platform focused on the targeted delivery of biologics across the blood-brain barrier (BBB). The company's flagship product, the TXP1 Brain Shuttle, utilizes a deimmunised VNAR antibody scaffold that specifically targets the transferrin receptor 1 (TfR1). This innovative approach enables efficient receptor-mediated transcytosis, allowing for the delivery of therapeutic agents directly into the central nervous system (CNS). The end uses of this technology primarily aim to address neurological disorders, highlighting its potential in advancing the next generation of CNS therapies. Ossianix's products are positioned to serve pharmaceutical companies engaged in CNS drug development, particularly in North America and Europe, where there is a significant need for effective treatments that can overcome the challenges posed by the BBB.Ossianix generates revenue through strategic partnerships and collaborations with pharmaceutical companies seeking to leverage its proprietary technology for drug delivery. The business model is primarily based on B2B transactions, where clients engage Ossianix to integrate the TXP1 Brain Shuttle into their therapeutic pipelines. Revenue structures may include milestone payments contingent upon achieving specific development goals, as well as royalties on future product sales. While specific pricing plans for the TXP1 and associated services are not publicly disclosed, it is anticipated that the company’s offerings are positioned to provide substantial value to partners by enhancing the efficacy of their CNS therapies. Through these arrangements, Ossianix aims to establish a sustainable revenue stream reflecting the growing demand for innovative solutions in the treatment of neurological conditions.Ossianix plans to expand its product offerings, including new iterations of the TXP1 Brain Shuttle, with anticipated launches in the upcoming years. The company is also targeting expansion into the European markets to increase its reach in the pharmaceutical sector. Following the recent venture funding from BioAdvance Ventures in October 2014, which was undisclosed in terms of financial specifics, Ossianix aims to utilize these funds to further development and market penetration efforts.

## Funding rounds

- Seed, May 23, 2013 — BioAdvance

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed